• Laura Gómez-Virgilio, Gabriela S Reyes-Gutiérrez, María-Del-C Silva-Lucero, Gustavo López-Toledo, and María-Del-C Cárdenas-Aguayo.
• Laboratory of Cell Reprogramming and Chronic-Degenerative Diseases, Department of Physiology, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.
• Gac Med Mex. 2022 Jan 1; 158 (4): 235-241.

AbstractAlzheimer's disease is a neurodegenerative disorder whose etiology continues to be discussed, to the point that there are different hypotheses that seek to clarify it, in addition to the fact that, given its multifactorial nature, there are different risk factors associated with its development. As regards diagnosis, advances in molecule detection techniques at femtomolar scales have allowed to distinguish between healthy and diseased subjects at relatively early stages, although there is still much to be done. Aducanumab is a monoclonal antibody targeted against Aβ, whose marketing approval by the Food and Drug Administration has been questioned by the international medical community, given the controversial results in clinical trials. Approval of this antibody as a disease-modifying treatment for Alzheimer's disease opens the door to continue using this type of treatments, but with different therapeutic targets, such as, for example, tau protein. Finally, given the population tendency towards longevity, conditions such as Alzheimer's disease are gaining epidemiological importance, which is why it is imperative to analyze and link what is being done in the social, familiar, clinical and research fields and, most importantly, to find those areas of opportunity for the benefit of the patient.Copyright: © 2022 Permanyer.

20 keywords...

hide…